Atlas Trials

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer

Clinical trial NCT03346811 · UNKNOWN

Trial details

NCT number
NCT03346811
Sponsor
Betta Pharmaceuticals Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Plasma EGFR Mutation-positive Lung Cancer
Start date
2017-11-18
Primary completion
2019-05-10
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.